Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain
Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitiv...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/9/2726 |
| _version_ | 1797555941889015808 |
|---|---|
| author | Angel Michael Ortiz Zuñiga Rafael Simó Octavio Rodriguez-Gómez Cristina Hernández Adrian Rodrigo Laura Jamilis Laura Campo Montserrat Alegret Merce Boada Andreea Ciudin |
| author_facet | Angel Michael Ortiz Zuñiga Rafael Simó Octavio Rodriguez-Gómez Cristina Hernández Adrian Rodrigo Laura Jamilis Laura Campo Montserrat Alegret Merce Boada Andreea Ciudin |
| author_sort | Angel Michael Ortiz Zuñiga |
| collection | DOAJ |
| description | Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE’s Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, <i>p</i> 0.024, CI 95% (0.609–0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral. |
| first_indexed | 2024-03-10T16:54:47Z |
| format | Article |
| id | doaj.art-41f80fbad7e7428f8632500f51336b8e |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T16:54:47Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-41f80fbad7e7428f8632500f51336b8e2023-11-20T11:10:06ZengMDPI AGJournal of Clinical Medicine2077-03832020-08-0199272610.3390/jcm9092726Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in SpainAngel Michael Ortiz Zuñiga0Rafael Simó1Octavio Rodriguez-Gómez2Cristina Hernández3Adrian Rodrigo4Laura Jamilis5Laura Campo6Montserrat Alegret7Merce Boada8Andreea Ciudin9Institut de Recerca Vall d’Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), 08035 Barcelona, SpainInstitut de Recerca Vall d’Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), 08035 Barcelona, SpainResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, 08028 Barcelona, SpainInstitut de Recerca Vall d’Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), 08035 Barcelona, SpainGMV Soluciones Globales Internet SAU, 28760 Valencia, SpainGMV Soluciones Globales Internet SAU, 28760 Valencia, SpainInternational Corporate Affairs, Alzheimer’s Disease, Eli Lilly and Co., 50019 Firenze, ItalyResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, 08028 Barcelona, SpainResearch Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, 08028 Barcelona, SpainInstitut de Recerca Vall d’Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), 08035 Barcelona, SpainIntroduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE’s Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, <i>p</i> 0.024, CI 95% (0.609–0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral.https://www.mdpi.com/2077-0383/9/9/2726type 2 diabetesmild cognitive impairmentAlzheimer’s disease |
| spellingShingle | Angel Michael Ortiz Zuñiga Rafael Simó Octavio Rodriguez-Gómez Cristina Hernández Adrian Rodrigo Laura Jamilis Laura Campo Montserrat Alegret Merce Boada Andreea Ciudin Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain Journal of Clinical Medicine type 2 diabetes mild cognitive impairment Alzheimer’s disease |
| title | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
| title_full | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
| title_fullStr | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
| title_full_unstemmed | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
| title_short | Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain |
| title_sort | clinical applicability of the specific risk score of dementia in type 2 diabetes in the identification of patients with early cognitive impairment results of the mopead study in spain |
| topic | type 2 diabetes mild cognitive impairment Alzheimer’s disease |
| url | https://www.mdpi.com/2077-0383/9/9/2726 |
| work_keys_str_mv | AT angelmichaelortizzuniga clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT rafaelsimo clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT octaviorodriguezgomez clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT cristinahernandez clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT adrianrodrigo clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT laurajamilis clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT lauracampo clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT montserratalegret clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT merceboada clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain AT andreeaciudin clinicalapplicabilityofthespecificriskscoreofdementiaintype2diabetesintheidentificationofpatientswithearlycognitiveimpairmentresultsofthemopeadstudyinspain |